Cipla signs agreement with Novartis for diabetes therapy Galvus range
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
To enable company to be future-ready by tapping potential in CDMO space
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Microsoft Cloud for Healthcare and Cognizant’s TriZetto healthcare products aim to enhance transparency for consumers and increase interoperability for providers and payers
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Acetazolamide is used to treat glaucoma
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
Subscribe To Our Newsletter & Stay Updated